{"transactions":[{"id":2137763,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":123124,"kind":"organization","name":"InvaGen Pharmaceuticals, Inc.","position":1,"cik":"0001759453","reported_name":"InvaGen Pharmaceuticals, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-10-13T20:52:42.000Z","date":"2022-10-11","kind":"sale","acquired":false,"shares":388888,"price":7.714,"value":2999882.032,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation (\"InvaGen\"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom (\"Cipla EU\"), and (iii) Cipla Limited, a company incorporated in India (\"Cipla Limited\") (each of InvaGen, Cipla EU and Cipla Limited, a \"Reporting Person\", and collectively, the \"Reporting Persons\"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the \"Issuer\") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the \"Share Repurchase\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-108589","document":"tm2228236-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759453/000110465922108589/tm2228236-1_4seq1.xml","form_type":"4"}}]}